Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
none appears on more than one
Alex Rogers is a seasoned private equity professional and alternative investment expert based in New York, NY, currently serving as Chief Financial Officer of Voyager Acquisition Corp. since August 2024. In this capacity, he is part of the management team guiding the SPAC's strategic direction, including its pending merger with Swiss oncology biotech VERAXA. He also serves as CFO of Voyager Acquisition Corp. II, which filed for a $220 million IPO in March 2026, targeting businesses in the technology, financial technology, and healthcare sectors. Alongside his SPAC roles, Rogers has been a Principal at Blue Ox Healthcare Partners since January 2019, where he is a member of the investment team and manages investor relations and communications.
Rogers brings over 15 years of experience in the alternative investment space, having worked across multiple capacities as a consultant, limited partner, general partner, and service provider. Prior to joining Blue Ox, he served as a Senior Director at MVision Private Equity Advisers. His deep expertise in private equity and investor relations has been instrumental in his work with Voyager's SPAC platform, which is led by CEO Adeel Rouf and Chairman Warren Hosseinion. Under this management team, the first Voyager SPAC (VACH) successfully completed its IPO with a trust value of approximately $221.1 million, and the second vehicle (VAII) is actively searching for a target with $220 million in capital.
Rogers's track record in the SPAC market includes involvement in two transactions with an aggregate capital deployment of approximately $441.1 million, with $220 million currently active or searching. His frequent underwriters include Cantor Fitzgerald & Co., and he has worked closely with associates such as Adeel Rouf and Warren Hosseinion. The merger completion rate for his SPAC vehicles stands at 50%, reflecting the ongoing process of the second vehicle. His multi-sector and multi-strategy investment approach, combined with his extensive network in the alternative investment community, positions him as a key figure in Voyager's efforts to identify and execute high-value business combinations in the healthcare, technology, and fintech spaces.
This record is keyed to SEC CIK 0002033323 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 51 institutional-holder rows on these vehicles, under 25 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.